PBX3在多发性骨髓瘤患者中的表达及与预后的关系-现代医学

PBX3在多发性骨髓瘤患者中的表达及与预后的关系

单位：1. 眉山市中医医院肿瘤血液科, 四川眉山 620000;
2. 眉山市中医医院内科, 四川眉山 620000;
3. 眉山市中医医院肾脏内科, 四川眉山 620000

分类号：R733.3

出版年·卷·期（页码）：2024·52·第十二期（1936-1941）

摘要：

目的：探讨B细胞白血病同源盒基因3(PBX3)在多发性骨髓瘤(MM)患者骨髓中的表达及与预后的关系。方法：选择2018年1月至2020年7月间我院收治的106例MM患者为研究对象。免疫组化法检测骨髓中PBX3表达，根据MM患者骨髓中PBX3表达情况分为PBX3阳性组(n=76)和PBX3阴性组(n=30)。其中4例患者随访中失访。根据MM患者3年预后分为存活组(n=63)和死亡组(n=39)。MM患者预后的影响因素采用多因素Cox回归分析；Kaplan-Meier法绘制MM患者不同PBX3表达的生存曲线。结果：与PBX3阴性组比较，PBX3阳性组DSⅢ期、国际分期系统(ISS)Ⅲ期、乳酸脱氢酶(LDH)≥245 U·L^-1及血小板计数(PLT)＜100×10⁹ L^-1的占比较高(P＜0.05)。多因素Cox回归分析显示，DS分期、ISS分期、危险分层、β2-微球蛋白(β2M)和PBX3表达均为MM患者预后的影响因素(P＜0.05)。PBX3阳性组的3年总存活率(50.00%)低于PBX3阴性组(83.33%)(P＜0.05)。结论：MM患者骨髓中PBX3阳性表达率较高，且PBX3表达与患者临床病理特征及预后密切相关。

Objective: To investigate the expression of pre-B-cell leukemia homeobox 3(PBX3) in the bone marrow of patients with multiple myeloma(MM) and its relationship with prognosis. Methods: From January 2018 to July 2020, 106 MM patients admitted to our hospital were selected as the study objects. The expression of PBX3 in bone marrow was detected by immunohistochemistry. Based on the expression of PBX3 in the bone marrow,patients were divided into PBX3 postive group(n=76) and PBX3 negative group(n=30). 4 patients were lost to follow-up during the follow-up visits. Complying with the 3-year prognosis, MM patients were divided into survival group(n=63) and death group(n=39). The influencing factors of prognosis in MM patients were analyzed by Cox regression analysis. Kaplan-Meier method was used to plot the survival curves of MM patients with different PBX3 expression. Results: Compared with PBX3 negative group, the proportions of Durie-Salmon(DS) stage III, international staging system(ISS) stage III, lactate dehydrogenase(LDH) ≥245 U·L^-1 and platelet count(PLT)<100×10⁹ L^-1 were higher in PBX3 positive group(P<0.05). Multivariate Cox regression analysis showed that DS stage, ISS stage, risk stratification, β2-microglobulin(β2M), and PBX3 were all influencing factors for the prognosis of MM patients(P<0.05). The 3-year overall survival rate of PBX3 positive group(50.00%) was lower than that of PBX3 negative group(83.33%)(P<0.05).Conclusion: The positive expression rate of PBX3 in the bone marrow of MM patients is relatively high, and the expression of PBX3 is closely related to the clinical pathological features and prognosis.

参考文献：

[1] 李红伟,司松环,杨靖,等.多发性骨髓瘤患者血清lncRNA PITPNA-AS1、lncRNA NORAD水平及其与患者预后的关系[J].东南大学学报(医学版),2024,43(3):450-455.
[2] MAURA F,BERGSAGEL P L.Molecular pathogenesis of multiple myeloma:clinical implications[J].Hematol Oncol Clin North Am,2024,38(2):267-279.
[3] OGANESYAN A,GHAHRAMANYAN N,MEKINIAN A,et al.Managing multiple myeloma in a resource-limited region:diagnosis and treatment in Armenia[J].Semin Oncol,2021,48(4-6):269-278.
[4] 刘灵娟,张一,高冲,等.血液系统疾病相关多原发癌的研究进展[J].现代医学,2023,51(3):416-420.
[5] HE X,XU Y,HUANG D,et al.P2X1 enhances leukemogenesis through PBX3-BCAT1 pathways[J].Leukemia,2023,37(2):265-275.
[6] WANG D,JIN X,LEI M,et al.USF1-ATRAP-PBX3 axis promote breast cancer glycolysis and malignant phenotype by activating AKT/mTOR signaling[J].Int J Biol Sci,2022,18(6):2452-2471.
[7] YAN T,WANG X,ZHOU D,et al.Circ_0003489 facilitates multiple myeloma progression by targeting miR-433-3p/PBX3 axis[J].Hematology,2022,27(1):951-959.
[8] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2015年修订)[J].中华内科杂志,2015,54(12):1066-1070.
[9] 杜昌宇.PBX3在宫颈癌中的表达及与临床病理参数和预后关系[J].中国计划生育学杂志,2018,26(10):904-908.
[10] ZHENG T,CHEN P,XU Y,et al.Comprehensive analysis of thirteen-gene panel with prognosis value in multiple myeloma[J].Cancer Biomark,2023,38(4):583-593.
[11] LUO X,WEI M,LI W,et al.PBX3 promotes pentose phosphate pathway and colorectal cancer progression by enhancing G6PD expression[J].Int J Biol Sci,2023,19(14):4525-4538.
[12] LI W F,HERKILINI A,TANG Y,et al.The transcription factor PBX3 promotes tumor cell growth through transcriptional suppression of the tumor suppressor p53[J].Acta Pharmacol Sin,2021,42(11):1888-1899.
[13] 司亚静,张建丽,郑雪莉.长链非编码RNA HNF1A-AS1对口腔癌细胞增殖、侵袭和EMT的影响[J].分子诊断与治疗杂志,2022,14(12):2044-2049,2054.
[14] 张慧,陈子翔,赵纯毅,等.PBX3在急性髓系白血病中的高表达及其临床意义[J].安徽医科大学学报,2022,57(12):2012-2018,2024.
[15] VIOL FERREIRA LOPES M A,HIGASHI F,CRUSOE E Q,et al.Impact of the lactate dehydrogenase in association with the international staging system prognostic score in multiple myeloma patients treated in real life[J].Hematol Transfus Cell Ther,2023,45(2):259-265.
[16] ELMENSHAWY N,FARAG N A,ATIA D M,et al.Prognostic relevance of concordant expression CD69 and CD56 in response to bortezomib combination therapy in multiple myeloma patients[J].Cancer Invest,2021,39(9):777-782.
[17] LU W,XU S,TAN S,et al.Comprehensive analysis and establishment of a prognostic model based on non-genetic predictors in multiple myeloma[J].Cancer Biomark,2023,38(1):49-59.
[18] 洪金全,何毅辉,黄建新.真核翻译起始因子4E在初治多发性骨髓瘤患者中的表达和临床意义[J].中国实验血液学杂志,2023,31(5):1421-1425.
[19] 任梅,石培民,谢静,等.血清CXCL9和IL-34水平检测对多发性骨髓瘤患者的疗效监测及其预后价值[J].现代检验医学杂志,2023,38(5):127-132.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录